This article is more than 5 years old. Information may no longer be current.

Updated dry eye, meibomian gland dysfunction treatment cleared by FDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MORRISVILLE, N.C. — The U.S. Food and Drug Administration has cleared the second generation of the LipiFlow Thermal Pulsation System, according to a press release from TearScience.

The device is designed to help treat evaporative dry eye by liquefying and evacuating obstructions in the meibomian glands, the release said.

The first generation of the device achieved FDA approval in July 2011. The second-generation device allows the physician to treat both eyes at once and includes an upgraded graphical interface, according to the release.

The new device also can store treatment records on electronic medical record servers, reducing the need to manually document treatment, the release said.

The updated LipiFlow will be commercially available in March, according to the release. Physicians now using the first-generation system will be upgraded to the new system.